Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time

0 Comments 2 view(s)

First Post-Merger Earnings Call for Jaguar and its Wholly-Owned
Subsidiary, Napo Pharmaceuticals, Regarding Sales of Napo’s FDA-Approved
Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic
Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on
Antiretroviral Therapy

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a commercial stage
natural-products pharmaceuticals company focused on developing novel,
sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis, announced that its
conference call originally scheduled for 4:30 p.m. Eastern Time today
has been rescheduled for 5:45pm Eastern Time today. The call is being
hosted to review year-to-date sales figures for Jaguar and Napo
Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar
focused on human health and the ongoing commercialization of, and
development of follow-on indications for, Mytesi®
(crofelemer), Napo’s first-in-class, FDA-approved anti-secretory human
prescription drug.

The merger of Jaguar Animal Health and Napo became effective July 31,
2017. As a result, the quarterly report Jaguar will be filing on
November 14, 2017 on Form 10-Q with the U.S. Securities and Exchange
Commission will only include Mytesi® sales for August and
September of this year. On today’s call, Jaguar’s CEO and members of the
Company’s sales and marketing management team will review Mytesi®-related
commercial activities and results for the period of January to July of
2017, when Napo was still a private company, in addition to discussing
Mytesi® launch activities and sales performance following the
merger, for the period of August through October of 2017, as well as
current and planned commercial activities intended to grow Mytesi®
sales.

The management team will also review development activities focused on
planned follow-on indications for Mytesi®.

Conference Call Dial-In Instructions

Investors interested in listening to the live call should dial
888-394-8218 (Toll Free), 323-701-0225 (International). Please ask the

Full story available on Benzinga.com